BGOG-cx-9

An Open-Label, Randomized, Phase 3 Clinical Trial of the checkpoint inhibitor REGN2810 versus Therapy of Investigator’s Choice Chemotherapy in Recurrent or metastatic Platinum-Refractory Cervical Carcinoma

Sponsor: Regeneron Pharmaceuticals, Inc

Participating sites:

  • CHU UCL Namur, site Sainte Elisabeth, Namur
  • UZ Leuven, Leuven
  • Clinique CHC Montlégia, Liège
  • Institut Jules Bordet, Bruxelles
  • CHU UCL St. Luc, Bruxelles
  • OLV Aalst, Aalst
  • CHU de Liège, site Sart Tilman, Liège